These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28291683)

  • 1. A PEGylated analog of short-length Neuromedin U with potent anorectic and anti-obesity effects.
    Inooka H; Sakamoto K; Shinohara T; Masuda Y; Terada M; Kumano S; Yokoyama K; Noguchi J; Nishizawa N; Kamiguchi H; Fujita H; Asami T; Takekawa S; Ohtaki T
    Bioorg Med Chem; 2017 Apr; 25(8):2307-2312. PubMed ID: 28291683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent Body Weight-Lowering Effect of a Neuromedin U Receptor 2-selective PEGylated Peptide.
    Kanematsu-Yamaki Y; Nishizawa N; Kaisho T; Nagai H; Mochida T; Asakawa T; Inooka H; Dote K; Fujita H; Matsumiya K; Hirabayashi H; Sakamoto J; Ohtaki T; Takekawa S; Asami T
    J Med Chem; 2017 Jul; 60(14):6089-6097. PubMed ID: 28657315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEGylated neuromedin U-8 shows long-lasting anorectic activity and anti-obesity effect in mice by peripheral administration.
    Masuda Y; Kumano S; Noguchi J; Sakamoto K; Inooka H; Ohtaki T
    Peptides; 2017 Aug; 94():99-105. PubMed ID: 28400225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.
    Kaisho T; Nagai H; Asakawa T; Suzuki N; Fujita H; Matsumiya K; Nishizawa N; Kanematsu-Yamaki Y; Dote K; Sakamoto JI; Asami T; Takekawa S
    Int J Obes (Lond); 2017 Dec; 41(12):1790-1797. PubMed ID: 28757640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide.
    Neuner P; Peier AM; Talamo F; Ingallinella P; Lahm A; Barbato G; Di Marco A; Desai K; Zytko K; Qian Y; Du X; Ricci D; Monteagudo E; Laufer R; Pocai A; Bianchi E; Marsh DJ; Pessi A
    J Pept Sci; 2014 Jan; 20(1):7-19. PubMed ID: 24222478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEGylation of Neuromedin U yields a promising candidate for the treatment of obesity and diabetes.
    Ingallinella P; Peier AM; Pocai A; Marco AD; Desai K; Zytko K; Qian Y; Du X; Cellucci A; Monteagudo E; Laufer R; Bianchi E; Marsh DJ; Pessi A
    Bioorg Med Chem; 2012 Aug; 20(15):4751-9. PubMed ID: 22771182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A potent neuromedin U receptor 2-selective alkylated peptide.
    Nishizawa N; Kanematsu-Yamaki Y; Funata M; Nagai H; Shimizu A; Fujita H; Sakamoto J; Takekawa S; Asami T
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4626-4629. PubMed ID: 28935264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).
    Peier A; Kosinski J; Cox-York K; Qian Y; Desai K; Feng Y; Trivedi P; Hastings N; Marsh DJ
    Endocrinology; 2009 Jul; 150(7):3101-9. PubMed ID: 19324999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of peripherally administered neuromedin U on energy and glucose homeostasis.
    Peier AM; Desai K; Hubert J; Du X; Yang L; Qian Y; Kosinski JR; Metzger JM; Pocai A; Nawrocki AR; Langdon RB; Marsh DJ
    Endocrinology; 2011 Jul; 152(7):2644-54. PubMed ID: 21586559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromedin U inhibits food intake partly by inhibiting gastric emptying.
    Dalbøge LS; Pedersen SL; Secher T; Holst B; Vrang N; Jelsing J
    Peptides; 2015 Jul; 69():56-65. PubMed ID: 25895852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake.
    Dalbøge LS; Pedersen SL; van Witteloostuijn SB; Rasmussen JE; Rigbolt KT; Jensen KJ; Holst B; Vrang N; Jelsing J
    J Pept Sci; 2015 Feb; 21(2):85-94. PubMed ID: 25521062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of potent and proteolytically stable human neuromedin U receptor agonists.
    De Prins A; Martin C; Van Wanseele Y; Skov LJ; Tömböly C; Tourwé D; Caveliers V; Van Eeckhaut A; Holst B; Rosenkilde MM; Smolders I; Ballet S
    Eur J Med Chem; 2018 Jan; 144():887-897. PubMed ID: 29329072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives.
    Niida A; Kanematsu-Yamaki Y; Asakawa T; Ishimura Y; Fujita H; Matsumiya K; Nishizawa N; Adachi Y; Mochida T; Tsuchimori K; Yoneyama-Hirozane M; Sakamoto J; Hirabayashi H; Fukui H; Takekawa S; Asami T
    Bioorg Med Chem; 2018 Feb; 26(3):566-572. PubMed ID: 29279243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small lipidated anti-obesity compounds derived from neuromedin U.
    Micewicz ED; Bahattab OS; Willars GB; Waring AJ; Navab M; Whitelegge JP; McBride WH; Ruchala P
    Eur J Med Chem; 2015 Aug; 101():616-26. PubMed ID: 26204509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and pharmacological characterization of a small-molecule antagonist at neuromedin U receptor NMUR2.
    Liu JJ; Payza K; Huang J; Liu R; Chen T; Coupal M; Laird JM; Cao CQ; Butterworth J; Lapointe S; Bayrakdarian M; Trivedi S; Bostwick JR
    J Pharmacol Exp Ther; 2009 Jul; 330(1):268-75. PubMed ID: 19369576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appetite-modifying actions of pro-neuromedin U-derived peptides.
    Bechtold DA; Ivanov TR; Luckman SM
    Am J Physiol Endocrinol Metab; 2009 Aug; 297(2):E545-51. PubMed ID: 19531638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central NMU signaling in body weight and energy balance regulation: evidence from NMUR2 deletion and chronic central NMU treatment in mice.
    Egecioglu E; Ploj K; Xu X; Bjursell M; Salomé N; Andersson N; Ohlsson C; Taube M; Hansson C; Bohlooly-Y M; Morgan DG; Dickson SL
    Am J Physiol Endocrinol Metab; 2009 Sep; 297(3):E708-16. PubMed ID: 19584200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cloning and expression patterns of neuromedin U and its receptors in pigs.
    Li X; Niu M; Su J; Ma Z; Jin M; Qiao W; Zhang Y; Feng Y; An N; Hou Y; Yang S; Chuan S; Lei Z
    Neuropeptides; 2017 Aug; 64():47-60. PubMed ID: 28434792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The discovery of neuromedin U and its pivotal role in the central regulation of energy homeostasis].
    Kirsz K; Zięba DA
    Postepy Hig Med Dosw (Online); 2012 Apr; 66():196-203. PubMed ID: 22706104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of neuromedin U (NMU), neuromedin S (NMS) and their receptors (NMUR1, NMUR2) in chickens.
    Wan Y; Zhang J; Fang C; Chen J; Li J; Li J; Wu C; Wang Y
    Peptides; 2018 Mar; 101():69-81. PubMed ID: 29288685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.